Skip to main content
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 2020 Mar 4;117(11):6023–6034. doi: 10.1073/pnas.1920008117

Loss-of-function BK channel mutation causes impaired mitochondria and progressive cerebellar ataxia

Xiaofei Du a,1, Joao L Carvalho-de-Souza b,c,1,2, Cenfu Wei a, Willy Carrasquel-Ursulaez d,3, Yenisleidy Lorenzo d, Naileth Gonzalez d, Tomoya Kubota b,c,4, Julia Staisch a,5, Timothy Hain e, Natalie Petrossian a, Michael Xu a, Ramon Latorre d, Francisco Bezanilla b,c,d, Christopher M Gomez a,6
PMCID: PMC7084159  PMID: 32132200

Significance

Genetic disruption of ion channels underlies several neurological diseases, suggesting that ionic disturbances are common neuronal stressors potentially amenable to therapies. The detailed intracellular pathways coupling ion channel mutations to neuronal damage are largely unknown. Here, we describe the finding of a single loss-of-function mutation in the BK channel in a young patient with progressive cerebellar degeneration. The mutant BK channel caused a profound dominant-negative effect on native channels, combined with reduced ion selectivity, leading to depolarization and depletion of mitochondria, and when delivered virally to mice, mimicked the disease. BK channel active drugs rescued the mutant cellular phenotype. These results point to the importance of mitochondrial ionic homeostasis in cerebellar disease and suggest therapeutic strategies.

Keywords: KCNMA1, ataxia, cerebellar degeneration

Abstract

Despite a growing number of ion channel genes implicated in hereditary ataxia, it remains unclear how ion channel mutations lead to loss-of-function or death of cerebellar neurons. Mutations in the gene KCNMA1, encoding the α-subunit of the BK channel have emerged as responsible for a variety of neurological phenotypes. We describe a mutation (BKG354S) in KCNMA1, in a child with congenital and progressive cerebellar ataxia with cognitive impairment. The mutation in the BK channel selectivity filter dramatically reduced single-channel conductance and ion selectivity. The BKG354S channel trafficked normally to plasma, nuclear, and mitochondrial membranes, but caused reduced neurite outgrowth, cell viability, and mitochondrial content. Small interfering RNA (siRNA) knockdown of endogenous BK channels had similar effects. The BK activator, NS1619, rescued BKG354S cells but not siRNA-treated cells, by selectively blocking the mutant channels. When expressed in cerebellum via adenoassociated virus (AAV) viral transfection in mice, the mutant BKG354S channel, but not the BKWT channel, caused progressive impairment of several gait parameters consistent with cerebellar dysfunction from 40- to 80-d-old mice. Finally, treatment of the patient with chlorzoxazone, a BK/SK channel activator, partially improved motor function, but ataxia continued to progress. These studies indicate that a loss-of-function BK channel mutation causes ataxia and acts by reducing mitochondrial and subsequently cellular viability.


Mutations in a wide array of ion channel genes underlie distinct forms of neurological disease. Prominent among these are the spinocerebellar ataxias (SCAs) that are a group of genetically diverse neurodegenerative diseases affecting the cerebellum and its connections. Approximately one-third of the nearly 30 genetically identified forms of autosomal-dominant cerebellar ataxia are due to mutations in ion channel genes, including genes for four distinct voltage-gated potassium channels (KV) (111). Missense mutations of the KCNA1 (Kv1.1), KCNC1 (Kv3.1), KCNC3 (Kv3.3), and KCND3 (Kv4.3) K+ channel genes underlie episodic or progressive ataxia syndromes, and some of them are associated with cognitive impairment and/or epilepsy (1, 37). The human KCNMA1 gene encodes the large-conductance, calcium- and voltage-activated K+ (BK) channel α-subunit. The BK pore-forming α-subunit contains seven transmembrane segments (S0 to S6) with an extracellular N terminus and an extensive intracellular C terminus containing two high-affinity Ca2+ binding sites (12). BK channels are activated by both membrane depolarization and cytosolic Ca2+. Mutations in the BK channel lead to a variety of clinical syndromes, correlated in part to the molecular phenotype, roughly divided into gain-of-function (GOF) and loss-of-function (LOF) (13). Du et al. identified a single missense mutation (D434G) in KCNMA1 that leads to a GOF change in BK channel and causes autosomal-dominant epilepsy with paroxysmal dyskinesias in a large kindred (14). Several individual patients have been reported with a KCNMA1 variant predicting a point mutation (variably designated as N995S/N999S/N1053S) in the BK channel associated with epilepsy without dyskinesia. Interestingly, whereas the GOF phenotype of the D434G mutant is due to an increase in the BK Ca2+ sensitivity, in the N995S mutant the BK GOF is due to a leftward shift of the conductance–voltage (G–V) curve. LOF mutations, which reduce either channel current or protein expression, are more consistently associated with cerebellar involvement and intellectual disability (ID), with variable presence of seizures, dyskinesias, and dystonia (13, 15). Moreover, mice lacking the BK channel developed cerebellar ataxia and Purkinje cell dysfunction (15). More recently, several rare KCNMA1 mutations producing an array of pathological phenotypes were reported (13, 16). However, other than the common theme of disturbed ion channel function, there is as yet little insight as to how the reported KCNMA1 mutations lead to neurological diseases (1719). Here, we describe a LOF mutation, identified by exome sequencing, in the KCNMA1 gene encoding BK channel α-subunit (BKG354S) associated with progressive cerebellar degeneration, ataxia, and cognitive impairment due to cellular toxicity and dysfunction/depletion of mitochondria.

We evaluated a 16-y-old girl who presented with cognitive impairment, multifocal dyskinesias, and progressive ataxia. Using exome sequencing, we identified a de novo mutation in the KCNMA1 gene predicting the mutation G354S in BK channels. The glycine residue 354 is in the BK selectivity filter, a highly conserved amino acid sequence among K+-selective ion channels. BK channels composed of the G354S mutant α-subunits (BKG354S) exhibit a dramatically reduced unitary conductance relative to BK channels bearing wild-type (WT) α-subunits (BKWT) and proportional reduction in the macroscopic K+ currents, suggesting no changes in protein abundance. Importantly, the mutation also reduces BK channel selectivity to K+ ions, increasing the relative permeability to Na+ ions. Expression of BKG354S also led to reductions in neurite outgrowth and cellular viability, together with depletion of mitochondria when expressed in cultured neuronal cells. Notably, application of the BK channel activator NS1619 (2022) activates the WT channels, while inhibiting the mutant BK channels, to improve viability and mitochondrial content in cultured cells. Viral delivery to neonatal mice of the BKG354S channel, but not the BKWT channel, caused impaired gait. Clinically, treatment of the patient with chlorzoxazone, a pharmaceutical SK/BK channel activator (23), slightly improved motor coordination scores and balance, although the ataxia continued to progress. This study describes an association of progressive ataxia with a mutation in the BK channel and supports the view that BK channel function, particularly in mitochondria, is critical for neuronal viability and is a potential mechanism for Purkinje cell degeneration and cerebellar ataxia.

Results

Clinical Phenotype and Identification of the BK Channel G354S Mutation.

The patient, a 16-y-old female, was noted to have ataxic gait and delayed motor milestones at the age of 18 mo. Clinical features are summarized in Table 1 and compared with those bearing previously reported KCNMA1 mutations (14, 1719, 24). She had two febrile seizures between 3 and 5 y of age. She was developmentally delayed, estimated to read at a first-grade level, and exhibited emotional outbursts. Her language comprehension was slightly subnormal, but she had an unintelligible speech due to severe dysarthria. Her motor coordination initially improved but lagged behind that of her younger sister, until at 8 y of age when she began to have slow deterioration in her gait and upper limb coordination. She developed scoliosis at age 14, but only required conservative management. At the age of 16, her neurological examination revealed slight difficulties with comprehension and following conversations, but good orientation and memory. She also showed coarse downbeat and gaze-evoked nystagmus in all directions; perioral, truncal, and limb dyskinesias; slightly spastic tone with bilateral Babinski signs; frank anarthria, intention tremor, past pointing, and dysdiadokinesia in her limbs; and severely wide-based and unsteady stance and gait. Her biological parents and younger sister are alive and doing well with no neurological complaints. Serial MRI scans from age 7 to 15 revealed severe and progressive cerebellar atrophy, most prominent in the midline, and no other abnormalities of cerebral hemispheres (Fig. 1A). The morphometric analysis estimated a 20% loss of cerebellar volume over 8 y.

Table 1.

Summary of clinical features in proband compared with subjects with other reported KCNMA1 mutations

BK mutations
LOF mutations GOF mutations
Symptoms S351Y (16) G354S G356R (16) G375R (16) N449fs*/C413Y (16) R458ter* (19) I663V (16) Y676Lfs*7 (17) P805L (16) G884L (18) D984N (16) D434G (14) N995S (23) N999S (23) N1053S (18)
Zygosity Het Het Het Het Compound het Homo Het Homo Het Het Het Het Het. Het Het
Age of onset Inf 18 mo Inf Inf NA Inf Inf 8 mo Inf 20 d Inf 2 y 9 y 20 mo 7 mo
Ataxia + + + + +
Seizure type Febrile Abs GTC/atonic NA Myoclonic/GTC2/3 Gen, focal dystonic Abs/GTC GME Atypical abs myoclonic
Dyskinesias/Dystonia NA + ++ NA + + ++ + ++ 4/7
Nystagmus + + NA + NA NA
DD/ID + + ++ ++ ++ ++ + ++ + ++ + + +
Cerebellar atrophy + + + + + +
Developmental anomalies Facial, digital + Skeletal Facial, visceral Facial NA NA NA NA NA NA

— indicates absent, + indicates present, and ++ indicates moderate to severe. abs, absent; DD/ID, developmental delay/intellectual disability; Gen, generalized; Het, heterozygous, Homo, homozygous; Inf, infancy; NA, not available.

Fig. 1.

Fig. 1.

Serial MRI scans and direct Sanger sequence of the patient with KCNMA1 gene c.1060G>A mutation. (A) Serial MRI scans of the patient from age 7 to 15 y. Midline sagittal T1-weighted images of the patient at 7 y and at 15 y of age demonstrating pronounced selective atrophy of the cerebellum. (B) Direct Sanger sequence of KCNMA1 gene mutation region of the patient, sister, and parents. (Left) Pedigree of the family with c.1060G>A AD mutation on the chromosome 10. (Right Upper) The direct representative sequence of KCNMA1 c.1060G region at exon 8. (Right Lower) The heterozygous mutation of c.1060G>A (p.G354S) in the patient. The box indicated the location of the mutation.

Whole-exome sequencing (WES), followed by targeted di-deoxy sequencing of proband, parents, and unaffected sister, confirmed four heterozygous de novo variants in the proband (SI Appendix, Table S1). The mutation most likely to be associated with the patient’s symptoms was a 1060 G>A mutation in exon 8 in the KCNMA1 gene, which encodes the BK channel, suggesting a G354S amino acid change in this protein (Fig. 1B).

This mutation was not present in any database, including the Exome Aggregation Consortium (ExAC) and gnomAD databases of aggregated WES data, or in 765 exomes sequenced at University of Chicago, including 322 other patients with ataxia. The residue G354 is conserved in the sequence of amino acids that forms the selectivity filter of K+ channels, 352-TVGYG-356. This motif is conserved in BK channels identified at least as far back as Drosophila (Fig. 2). In silico genetic prediction algorithms, such as SIFT and PolyPhen-2, that use sequence- and structure-based features and evolutionary conservation of amino acids predicted this substitution to be pathogenic (25, 26).

Fig. 2.

Fig. 2.

The G354S mutation is located in the highly conserved signature sequence “TVGYG” of potassium channels. (A, Left) Side view of two Aplysia BK subunits from structural studies by cryo-EM (Protein Data Bank [PDB]: 5TJ6). Color code: voltage-sensor domain (orange), pore domain (green), RCK1 domain (blue), and RCK2 domain (red). (A, Right) Close view of the selectivity filter with the G354 annotated. (B) TVGYG in KCNMA1 is conserved among species with TVGFG sequence in Aplysia’s BK channels instead of TVGYG in all other species shown. (C) The selectivity filter G354 residue from the BK channel is also conserved in the α-subunits of other human K+-selective channels.

Of the three other de novo variants identified in WES, a variant in SLC22A5 suggests that the patient is also a possible carrier of carnitine deficiency (27) (SI Appendix, Table S2), while the two others DYSF and BRAT1 are associated with recessively inherited syndromes (28, 29) and have been seen in the normal population (https://gnomad.broadinstitute.org/).

BKG354S Channels Have Dramatically Reduced K+ Conductance, and Lower Selectivity to K+.

The G354S mutation in BK channels is located in the channel selectivity filter, the narrowest part of the conducting pathway (30). Since G354 is one of the residues that coordinate K+ ions with its carbonyl group during conduction, we hypothesized G354S mutation would cause changes in the unitary conductance as well as in the ionic selectivity to K+. To study the effects of the G354S mutation on conductive properties of BK channels, we separately expressed BKG354S and BKWT channels in Xenopus oocytes. Based on the fact the proband bears both WT and a mutant allele of the KCNMA1 gene, we also coinjected oocytes with equal amounts of both WT and mutant complementary RNA (cRNA), to explore the possible dominant-negative effect of BKG354S on channels also containing BKWT: BKWT-G354S. In all three cases (BKWT, BKWT-G354S, and BKG354S), we recorded robust macroscopic K+ currents consistent with different levels of conductance (SI Appendix, Fig. S1A). Oocytes injected with 50 ng of cRNA for BKG354S showed on average (n = 10) 11% of the maximal current compared with oocytes injected with only 25 ng of cRNA for BKWT. Considering that oocytes can proportionally express channels according to the amount of cRNA injected, in the range between 25 and 50 ng, we could speculate that oocytes injected with 25 ng would express one-half of the number of channels than those injected with 50 ng. Therefore, the 11% translates to 5.5% when normalized by the amount of cRNA injected. The oocytes injected with both types of cRNA, WT and mutant, 25 ng each, served to probe the dominant-negative effect of BKG354S on heterochannels, the BKWT-G354S. If the oocytes were to express both channels equally but independently, without forming heterochannels, the level of current recorded from these oocytes would be at least the same as in those oocytes expressing BKWT only. Surprisingly, the oocytes injected with 25 ng of each cRNA for BKWT and BKG354S showed 45% of the currents from the BKWT group of oocytes (SI Appendix, Fig. S1B). We also analyzed the kinetics of the K+ current activation. The currents from BKG354S were activated up to two orders of magnitude slower than the currents from BKWT. Interestingly, the time constants from BKWT-G354S were only two to six times slower than the currents from BKWT (SI Appendix, Fig. S1C). Altogether, these data strongly suggest the BKWT and BKG354S coassemble to form heterochannels and that the BKG354S channels exert a dominant-negative effect on BKWT-G354S heteromers.

Currents Recorded from BKG354S in Oocyte’s Macropatches.

Voltage clamping of macropatches of membranes expressing BKG354S also showed reduced currents compared to a comparable experiment with membranes expressing BKWT. Since the activation of BK channels is controlled by voltage as well as by intracellular concentration of Ca2+, very low intracellular Ca2+ concentration in cut-open oocyte experiments results in channel activation at very positive voltages (with V1/2 around +170 mV), well beyond the efficient range in the cut-open oocyte preparation. Experiments with macropatches are appropriate for a wider range of voltages and have the additional advantage that Ca2+ concentration can be controlled both inside and outside the membrane (Fig. 3 A and B). Channel activation in macropatches over a voltage range between −100 to +250 mV using an intracellular Ca2+ concentration of about 40 nM revealed a leftward shift in the voltage-activation curves in macropatches expressing BKG354S compared with BKWT. However, at a 100 μM internal Ca2+ concentration, both mutant and BKWT have similar voltage dependence and half-activation voltages (Fig. 3C). Both the BKWT and BKG354S are sensitive to Ca2+; however, the smaller Ca2+-induced leftward shift of the G–V in the mutant suggests that its apparent Ca2+ sensitivity is less than that of the WT BK, further exacerbating the LOF phenotype. Noise analysis of the K+ conductance revealed a single-channel conductance of only 13.2 ± 1.5 pS (n = 5), a dramatic decrease compared to the single-channel conductance of around 180 to 200 pS from BKWT in symmetrical 110 mM K+ (Fig. 3D). Notably, the 13 pS we found for K+ conductance of BKG354S is 6.5% of that of BKWT (203 pS), which is a value very close to the 5.5% estimated with macroscopic currents from the cut-open oocytes experiments (SI Appendix, Fig. S1).

Fig. 3.

Fig. 3.

Characterization of BKG354S mutant ionic currents. (A) Representative BKWT ionic currents evoked by voltage steps from −200 to +250 range in 10-mV steps. Holding potential was −100 mV and the records made in nominal absence of internal Ca2+ (≅40 nM Ca2+). (B) BKG354S macroscopic currents in the same conditions as in A. (C) Relative tail currents vs. voltage [(Itail/Itail,max)–V] curves were obtained from experiments with ≅40 nM internal Ca2+ (as those shown in A and B; black circles) and at 100 μM Ca2+ (red circles). Continuous lines are best fits to the data using Eq. 2 (SI Appendix, SI Materials and Methods). For the BKWT channel, parameters were (mean ± SEM): V1/2 = 174 ± 3 mV, z = 1.21 ± 0.05 at [Ca2+]i = 40 nM, n = 10; V1/2 = −38 ± 6 mV, z = 1.41 ± 0.03 at [Ca2+]i = 100 μM, n = 7. For the BKG354S channel, parameters were (mean ± SEM): V1/2 = 131 ± 3 mV, z = 1.14 ± 0.03 at [Ca2+]i = 40 nM, n = 10; V1/2 = −50 ± 4 mV, z = 1.24 ± 0.04 at [Ca2+]i = 100 μM, n = 6. (D and E) Representative nonstationary noise analysis of BKWT and BKG354S currents, respectively. Inside-out patches were held at 0 mV and pulsed 200 times to 250 mV (BKWT) or 150 mV (BKG354S) during 10 ms. The intracellular (bath) solution was formulated for a Ca2+ concentration of 40 nM. The red lines are a fit to the data using Eq. 3 (SI Appendix, SI Materials and Methods). For BKWT (D), considering a 250 mV driving force (the experiment was done in symmetrical K+) and i = 50.8 pA, the patch had an average single-channel conductance (γi) of 203 pS. For BKG354S (E), γi was reduced compared with that of the WT channel with a value of 12 pS (i = 1.8 pA and 150 mV of driving force).

We also compared the K+ selectivity of BKG354S with BKWT by recording voltage-activated currents in symmetrical condition (140 mM K+ in both sides of the membrane) and under biionic condition (140 mM Na+ in the intracellular side and 140 mM K+ in the extracellular side of the membrane). The reversal potential was zero in symmetrical condition for both BKWT and BKG354S (Fig. 4 A and B, upper traces, and Fig. 4 C and D, Kext/Kint). Under biionic condition, the reversal potential was undetermined for BKWT (greater than +100 mV [n = 3]) and +40 ± 3 mV (n = 3) for BKG354S (Fig. 4 A and B, lower traces, and Fig. 4 C and D, Kext/Naint). These data confirm previous results showing no measurable permeation can be detected for Na+ in the case of the BKWT. From the reversal potential for the BKG354S channel in biionic condition, we calculated a PK+:PNa+ ratio of 4.8 (Fig. 4; Materials and Methods). This result indicates a considerable loss of K+ selectivity in BKG354S, and it agrees with the loss of selectivity caused by the analog mutation in the Shaker K+ channel selectivity filter (31).

Fig. 4.

Fig. 4.

The BKWT channel and the BKG354S mutant channel display different selectivity. Raw current traces from BKWT (A), or BKG354S channels (B), from either 140 mM K+ or 140 mM Na+ in the internal (bath) solution. Currents were recorded from excised, inside-out membrane patches, with 140 mM K+ in the extracellular (pipette) solution. Currents were activated by a step to 200 mV, followed by voltage pulses ranging from 200 to −100 mV (100 to −20 mV for the mutant), in 10-mV decrements. Leak and capacitive currents were subtracted using a P/-8 subtraction protocol (53). (C and D) Isochronal ItailV curves were taken from the records shown in A and B, respectively, in the presence of internal K+ (Kext/Kint, circles) or Na+ (Kext/Naint, squares), to determine the reversal potential for each case.

Recording of BKG354S Expressed in HEK Cells.

Additionally, we used the HEK cell system to express and compare BKWT and BKG354S channels. These electrophysiological experiments were particularly important since HEK cells are a human cell line. Consistent with the reduction of K+ currents seen when BKG354S was expressed in Xenopus oocytes, macroscopic currents recorded in inside-out patches on cells expressing BKG354S showed a reduction in the macroscopic K+ currents compared to cells expressing BKWT (Fig. 5 A and B). Also confirming the oocytes experiments, the voltage activation curve for the BKG354S mutant at 40 nM Ca2+ was leftward shifted by approximately −51 mV (Fig. 5C). More importantly, the single-channel conductance of the mutant channel (10 ± 2 pS) as determined by noise analysis was dramatically reduced compared to that of the BKWT channel (172 pS; cf. Fig. 5 D and E).

Fig. 5.

Fig. 5.

Characterization of BKWT and BKG354S ionic currents in HEK cells. (A) Macroscopic K+ currents in an inside-out membrane patch expressing BKWT channels. BKG354S currents were evoked by voltage steps from −120 to 350 mV from a prepulse of −80 in 10-mV steps returning to −80 mV. The holding potential was 0 mV. (B) BKG354S macroscopic currents elicited by voltage pulses from 0 to 330 mV in 10-mV steps, returning to 60 mV. The stimulation protocol consisted of a prepulse of −80 mV, followed by voltage pulses in the range of 0 to 330 mV with increments every 10 mV, returning to 60 mV. (C) Normalized tail currents (Itail/Itail,max) vs. voltage data. The solid lines are the best fit to the data using Eq. 2 (SI Appendix, SI Materials and Methods). For the BKWT channels, parameters were as follows (mean ± SEM; n = 3 [red]): V1/2 = 185 ± 16 mV, z = 0.88 ± 0.02; BKα G354S, n = 7. For the BKG354S, parameters were as follows (mean ± SEM; n = 7 [blue]): V1/2 = 134 ± 16 mV, z = 0.84 ± 0.03. All data were obtained in the nominal absence of Ca2+. (D) Representative nonstationary noise analysis of BKWT macroscopic currents. The patch was held at −80 mV and pulsed 200 times at 200 mV taken in the tail. The stimulation protocol consisted of a prepulse of −80 mV, followed by 200 pulses of 200 mV, returning to −20 mV. Noise analysis was done using the tail currents. Holding potential was 0 mV. The patch had 6,110 active channels with an average single-channel conductance of 172 pS. The average single-channel conductance was 170 ± 3 pS (n = 7). (E) Representative nonstationary noise analysis of G354S mutant macroscopic currents. Currents were evoked using a prepulse of −80 mV, followed by 200 pulses of 130 mV, returning to 60 mV. Noise analysis performed using the K+ currents elicited by the 130-mV pulses. The patch had 2,180 active channels with an average single-channel conductance of 9 pS. The average single-channel conductance was 10 ± 2 pS (n = 5).

Taken together, our functional results strongly suggest that mutation G354S in BK channels induces a LOF by decreasing the unitary conductance of the channel, and by a loss of selectivity to K+. The data also show that the reduction in G354S macroscopic currents is mainly due to the decrease in single-channel conductance and not to reduced channel expression. Moreover, our data from BKWT and BKG354S channels expressed together in oocytes suggest that BKG354S protein exerts a dominant-negative effect when coassembled with BKWT in the same heterochannel (SI Appendix, Fig. S1).

NS1619 is a synthetic benzimidazole derivative, and it is a specific BK channel activator in the micromolar range (22). The compound produces a reversible dose-dependent leftward shift antagonized by the scorpion toxin charybdotoxin. Gessner et al. (32) proposed that NS1619 activates BK channels by interacting with the S6/RCK1 linker. Fig. 6 AC shows that NS1619, as reported previously, robustly activates BKWT in HEK cell. Conversely, we found that the NS1619 behaves as a potent antagonist of the BKG354S mutant channel (Fig. 6 DF).

Fig. 6.

Fig. 6.

Effect of NS1619 on BKWT and BKG354S macroscopic currents. (A) BKWT macroscopic currents. The voltage protocol consisted of a prepulse of −80 mV, followed by voltage pulses in the range of −80 to 250 mV with increments every 10 mV, returning to −80 mV. The holding potential was 0 mV. (B) BKWT macroscopic currents in the presence of NS1619 added to a final concentration of 10 μM. The stimulation protocol consisted of a prepulse of −80 mV, followed by voltage pulses in the range of −80 to 250 mV with increments every 10 mV, returning to −80 mV. The holding potential was 0 mV. BKWT DNA transfected 250 ng/μL. (C) BKWT currents vs. voltage (I/V) curve (red) and BKWT currents vs. voltage (I/V) curve in the presence of 10 μM NS1619 (light red; n = 3). (D) BKG354S macroscopic currents. The voltage protocol consisted of a prepulse of −80 mV, followed by voltage pulses in the range of −80 to 230 mV with increments every 10 mV, returning to 60 mV. The holding potential was 0 mV. (E) BKG354S macroscopic currents in the presence of 10 μM NS1619 added to a final concentration of 10 μM. (F) BKG354S current vs. voltage curve (blue) and BKG354S current vs. voltage curve in the presence of 10 μM NS1619 (light blue). The voltage protocol consisted of a prepulse of −80 mV, followed by voltage pulses in the range of −80 to 230 mV with increments every 10 mV, returning to 60 mV. BKG354S DNA transfected 450 ng/μL.

The BKG354S Mutation Reduces Neurite Outgrowth.

To investigate the effect of the BKG354S mutation on differentiation in cultured mammalian cells, we transfected BKWT or BKG354S into PC12 cells, which undergo differentiation into neuronal phenotype in response to nerve growth factor (NGF). Upon induction with NGF for 24 and 48 h, we observed a significantly reduced total neurite length in cells expressing BKG354S channel compared to BKWT in 48 h (Fig. 7 AC and F). The percentage of cells bearing neurites was similar between cells expressing BKWT and BKG354S channels (Fig. 7 B, C, and E). To test whether reduced neurite outgrowth of the PC12 cells expressing the BKG354S channel could be attributed to BK channel function, we incubated cells in the BK channel activator NS1619. The neurite outgrowth in a PC12 cell expressing BKG354S channels was improved after treatment with NS1619 at 30 μM, although it did not reach normal values (Fig. 7D). The average NGF-induced neurite length for cells expressing BKG354S, compared to BKWT, was increased 18.87 ± 2.31% after 24 h with NS1619 and 29.20 ± 3.12% after 48 h with NS1619 (cf. Fig. 7 F and G).

Fig. 7.

Fig. 7.

Cells expressing the mutant BKG354S channel have reduced neurite outgrowth and cell viability, which is rescued by NS1619. (A and B) Both BKWT and BKG354S channels locate on the cell membrane in the representative confocal images with or without NGF stimulation. Detectable BK labeling can be seen in PC12 pCDNA3-only transfection because of possible endogenous expression. After 24 h in the presence of NGF, no neurites are present in cells expressing the mutant, although a systematic check shows no difference between cells expressing BKWT or BKG354S. Quantitative analysis of data present in E and F. (C and D) Representative low- and high-magnification images of PC12 cells transiently cotransfected pEGFP with pcDNA3, BKWT, and BKG354S channels at 48 h with NGF induction with (C) or without (D) NS1619 treatment. (E–G) Quantitation of average percentage of neurites per cell and neurite length (n ≥ 6; *P < 0.05; **P < 0.01). (H) Representative fluorescence dot blots of FITC-Annexin V and propidium iodide (PI). PI-stained HEK cells transiently transfected with pcDNA3, BKWT, or BKG354S channels without (Upper row) or with (Lower row) 30 μM NS1619 treatment (n ≥ 6; *P < 0.05; **P < 0.01). (I) Quantitation of FITC-Annexin-V– and PI-positive cells and cell viability in PC12 cells transiently transfected with pcDNA3, BKWT, or BKG354S channels without (Upper row) or with (Lower row) 30 μM NS1619 treatment (n ≥ 6; *P < 0.05; **P < 0.01).

The BKG354S Mutation Reduces Cell Viability.

When assessed by flow cytometry, PC12 cells expressing BKG354S exhibited 1.6-fold greater degree of cell death compared to cells expressing BKWT (Fig. 7 H and I). To test whether the reduced viability of the PC12 cells expressing the mutant channel could be attributed to BK channel function, we incubated cells in the BK channel activator NS1619. Cell death associated with BKG354S-expressing cells was corrected by pretreatment of cells with NS1619 at 30 μM and was similar to control BKWT cells (Fig. 7 H and I); the similar data were obtained from HEK cells.

Since BKG354S is toxic when expressed in HEK or PC12 cells that express native endogenous BK channels, we hypothesized that toxicity of the low-conductance BKG354S mutant may result from a dominant-negative effect, eliminating critical endogenous ordinary BK channel currents. Alternatively, the altered ion selectivity of the BKG354S mutant may disrupt Na+ concentration gradient, leading to loss of membrane potential. In either case, these results suggest that normal BK channel activity is important for the viability of these cultured cells. To test this, we used siRNA specific for BK channel α-subunit, the KCNMA1 gene product of BK channels, to knock down endogenous BK channels in PC12 cells, and compared the viability of PC12 cells between siRNAKCNMA1 and siRNAControl. Interestingly, cells depleted of their endogenous BK channels exhibited increased cell death compared to control cells and comparable to those transfected with the mutant BKG354S (Fig. 7 H and I); however, NS1619 was not able to rescue the cells treated with siRNAKCNMA1. This result suggests that, in cultured cells, cellular viability is dependent on the presence of normal BK channel function. The protection by NS1619 may result from either activation of endogenous BK channels or the selective blockade of the BKG354S mutant channels, or, most likely a combination of the two effects.

The BKG354S Mutation Traffic to Plasma Membrane and Mitochondria.

Many ion channel mutations affect subcellular trafficking or membrane insertion of the channel proteins. BK channels are normally present on multiple subcellular organelles in addition to the plasma membrane. To test whether BKG354S mutant and BKWT channels localize equally in the plasma membrane and other organelles, we subjected transfected cell lysates to subcellular fractionation and analysis by immunoblotting using HEK cells. The 100-kDa BK channel polypeptides were found present in the plasma membrane fraction of untransfected and to an increased, but equivalent extent in cells transfected with either BKG354S or BKWT plasmids (Fig. 8 A and C). Also, there was a detectable 100-kDa polypeptide present in mitochondrial fractions in both untransfected cells and cells transfected with BKG354S and BKWT constructs (Fig. 8 B and C).

Fig. 8.

Fig. 8.

The mutated BKG354S channel induces a selective toxicity on mitochondria. (A) The protein level of BKWT and BKG354S in membrane fraction remains constant. (B) The protein level of BKG354S in the mitochondrial fraction and the mitochondrial marker VDAC are decreased proportionally. (C) Quantitation of protein levels in A and B (n ≥ 6; *P < 0.05; **P < 0.01; ***P < 0.001). (D and E) Representative blot (D) and quantitation (E) show NS1619 recovered the protein levels of BK channel and mitochondria. (F and G) OXPHOS proteins were decreased in cells expressing BKG354S relative to BKWT-expressing cells. (H and I) HEK cells overexpressing BKWT or BKG354S are stained with mitochondrial indicator Tomm20 in red; BKWT and BKG354S are stained with anti-BK antibody in green. Representative images show colocalization of BK and mitochondria with or without NS1619 treatment. The intensity of mitochondrial indicator Tommo20 is decreased in BKG354S-expressing cells. NS1619 recovered the colocalization pattern between BKG354 channel and mitochondria (I).

To characterize the subcellular distribution of the BKG354S and BKWT channels morphologically, we examined HEK and PC12 cells transiently transfected with BKWT or BKG354S channels by immunofluorescence labeling using BK channel-specific antibodies. HEK cell transiently expressing either BK channel displayed diffuse membrane fluorescence with no pattern difference between BKG354S or BKWT channels (Fig. 8H). Colocalization analysis using mitochondrial probe MitoTracker Red also showed that both BKWT and BKG354S channels are expressed in mitochondria, although, as described below, at different levels (Fig. 8H).

The BKG354S Mutation Causes Selective Toxicity to Mitochondria.

We noticed that the intensity of the 100 kDa band in the mitochondria was consistently lower in cells expressing the BKG354S compared with BKWT when normalized to cellular GAPDH protein (Fig. 8C). To investigate whether this reduction was due to selective loss of BK channels in mitochondria, we compared the signal for the mitochondrial voltage-dependent anion channel (VDAC), as a marker for the mitochondrial compartment. The signal for VDAC was also consistently reduced by 50% relative to cells transfected with the BKWT channel or pcDNA3 control as assessed by immunoblotting (Fig. 8 B and C). However, when we normalized the BKWT or BKG354S levels in the mitochondrial fraction to the VDAC protein signal in the same fractions, there was no difference between cells expressing the BKWT or BKG354S mutant channel (Fig. 8 B and C). This suggests that, rather than selective mitochondrial loss of BK channels in cells expressing BKG354S, the mutation itself leads to a reduction in mitochondrial content. To test whether the effect of BKG354S on normal BK channel currents indicated a critical dependence of mitochondria on BK channels, we used siRNA KCNMA1 in HEK cells to knock down BK channels. Genetic silencing of BK channels led to reduced BK channels both in the membrane and mitochondrial fractions (Fig. 8 AC).

In addition, knockdown of endogenous BK channels was also accompanied by a decrease in the amount of VDAC protein in cells, supporting the idea that loss of BK channel activity reduced mitochondrial content (Fig. 8 B and C). To determine whether BK mutation affects components of the mitochondrial respiratory pathway, we examined several proteins of electron transport chain complexes. Levels of Complex I subunit NDUFB8, Complex II subunit, Complex III subunit Core 2, Complex IV subunit II, and ATP synthase subunit α, all components of the mitochondrial oxidative phosphorylation metabolic pathway (OXPHOS), were decreased in cells expressing BKG354S relative to BKWT-expressing cells (Fig. 8 F and G).

To compare the subcellular distribution of BKG354S and BKWT in mitochondria, we transiently transfected HEK cells, because of their superior resolution of subcellular compartments. We stained cells expressing BKWT or BKG354S with Tommo20 for mitochondria (red) and immunolabeled BK channels with anti-BK channel antibody (green). Fig. 8 H and I shows that the intensity of mitochondrial labeling was decreased in BKG354S-expressing cells compared with BKWT-expressing cells. Colocalization of Tommo20 and BK channel antibody also revealed a significantly lower immunolabeling signal in BKG354S than that in BKWT (Fig. 8 H and I).

Furthermore, silencing of BK channels using siRNA KCNMA1 led to a reduction of the mitochondrial labeling intensity for Tommo20 compared with siRNA Control (SI Appendix, Fig. S2 E and F).

Finally, to test whether the reduced mitochondrial content was related to BK channels affected by the presence of BKG354S subunit(s), we also treated cells transiently expressing BKWT or BKG354S channels with NS1619, known to improve neurite outgrowth and protect from cell death in cells expressing BKG354S channels. Fig. 8D shows that pretreatment of HEK cells expressing BKG354S channels with NS1619 protected the reduction of mitochondrial VDAC protein. However, treatment with NS1619 could not protect cells and prevent reduction of mitochondrial content in cells treated with KCNMA1-specific siRNA (Fig. 8 D and E and SI Appendix, Fig. S2 B and C). This suggests that mutation in BKG354S specifically affects channel function, and a drug acting as NS1619 might be protective in some ataxia patients.

Mitochondria Ultrastructure Is Disrupted by the BKG354S Mutation.

We performed electron-microscopic (EM) image analysis of mitochondrial content and ultrastructure in stably expressing BKWT and BKG354S cells (Fig. 9 AC). Mitochondria in BKG354S-expressing cells are fewer in number (Fig. 9C) and have abnormal-appearing cristae compared with BKWT and pcDNA3-expressing cells (Fig. 9B). Quantification reveals a 58.89 ± 4.62% reduction in mitochondrial number in BKG354S-expressing cells compared with BKWT and pcDNA3-expressing cells. In addition, 44.36 ± 4.78% of mitochondria have distended and disordered cristae in BKG354S stable expressing cells (Fig. 9C).

Fig. 9.

Fig. 9.

Abnormal mitochondrial ultrastructure and decreased mitochondrial potential in HEK cells overexpressing BKG354S, which can be rescued by NS1619. (A) Representative EM images show increased abnormal mitochondria in BKG354S overexpression cell compared with a population of normal mitochondria in pcDNA3 and BKWT overexpression cell. (B) Representative EM images show a diverse pattern of abnormal mitochondrial cristae in BKG354S mutation. (C) Quantitation of number of mitochondria per cell and percentage of abnormal cristae (n ≥ 6; *P < 0.05; **P < 0.01; ***P < 0.001). (D and E) HEK cells overexpressing BKWT or BKG354S are stained with MitoTracker green in green and TMRM in red. Representative images of TMRM decreased in BKG354S overexpression cell compared with that in pcDNA3 and BKWT overexpression cell (D); however, NS1619 treatment was able to recover TMRM expression in BKG354S overexpression cell (E). (F) Quantitation of TMRM and MitoTracker integrated intensity in D and E (n ≥ 6; **P < 0.01).

Mitochondria Dynamics Change and Potential Decreased in Live BKG354S Mutation Cells.

To observe dynamic changes of mitochondrial fusion and fission affected by the BKG354S mutation, we used MitoTracker Red, to stain live PC12 cells stably expressing BKWT, BKG354S, or pCDNA3. Live-cell imaging indicated grossly reduced content of mitochondria in cells expressing the BKG354S mutation (Movies S5 and S6) compared with cells expressing BKWT and control (Movies S1–S4). Elongated and interconnected fusion mitochondrial forms are predominant in cells expressing BKWT and control. In contrast, fragmentated fission forms are more prevalent in cells expressing the BKG354S mutation.

To investigate whether the BKG354S affects mitochondrial membrane potential in addition to its effect on mitochondrial fusion and fission, we used fluorescent probes TMRM and MitoTracker green to monitor the mitochondrial membrane potential in BKG354S stably expressing cells compared with BKWT and pcDNA3 stably expressing cells (Fig. 9 DF). The integrated intensity of TMRM/MitoTracker was decreased 43.5 ± 3% in BKG354S stably expressing cells compared to BKWT and pcDNA3 stably expressing cells (Fig. 9F). NS1619 treatment of BKG354S stably expressing cells was able to rescue the integrated intensity of TMRM/MitoTracker to 81.4 ± 4.4% that of control. Thus, NS1619 restored the membrane potential in a significant number of mitochondria in cells expressing BKG354S. These results indicate that impaired gating of the BKG354S mutation is directly responsible for depolarized or dysfunctional mitochondria.

BKG354S Causes Ataxia in Mice.

Because mice with targeted deletion of the BK channel α-subunit develop ataxia, we hypothesized that the LOF BK channel mutation acts in a similar fashion. To test for a direct effect of BKG354S on cerebellar function, we engineered adenoassociated virus 9 (AAV9)-based expression vectors to deliver BKWT or mutant BKG354S channels to neonatal mice. We injected 2 μL at 1 × 1012 vg/μL of AAV9-BKWT or AAV9-BKG354S into mouse intracerebroventricularly at postnatal day 0 (P0) (33). Mice tolerated the injections well and developed normally with no visible neurological deficits initially. Analysis of the histological features of the cerebellar cortex shows no obvious difference between mice injected with BKG354S vs. BKWT channel, a finding similar to that of BK knockout mice. To investigate whether the mutant BK channel expression affects motor function, AAV9-BKWT– or AAV9-BKG354S–treated mice were studied on a motorized treadmill equipped with a high-speed digital camera (DigiGait) (Mouse Specifics) (34) at 40 and 80 d of age to quantitatively assess 20 gait and limb movement parameters, for both left and right sides and both forelimb and hindlimb. After post hoc correction, significant abnormalities of motor temporal and spatial parameters, either unilaterally or bilaterally, were seen at P40 in 42% and at P80 in 55% of parameters. From these parameters, an ataxia coefficient is generated by DigiGait software. The coefficient of ataxia increased from 11.45 ± 1.4% and 8.7 ± 2.4% to 40.78 ± 2.3% and 52.36 ± 3.3% for both left and right hindlimbs, respectively, in AAV9-BKG354S mice from 40 to 80 d of age (SI Appendix, Fig. S3). SI Appendix, Fig. S3 displays representative plots gait parameters that were significantly different and impaired in the mice receiving BKG354S compared to those injected with BKWT. These findings directly implicate the role of this mutant channel in the clinical manifestations of ataxia in these mice.

SK/BK Channel Activator Improves Coordination in the Patient.

Potassium channel-activating drugs have recently shown some benefit in treating ataxia (35, 36). Presently, there are not pure BK channel activators approved for use in patients by the Food and Drug Administration. Chlorzoxazone is a mixed SK/BK channel activator marketed under the name Parafon Forte. We assessed the effects of this drug on motor performance in this patient. The patient was assessed semiquantitatively using the Scale for Assessment and Rating of Ataxia (SARA) rating scale by three examiners before treatment, two of whom were “blinded” as to treatment. The mean SARA score of this patient was 20.7 before the initiation of therapy (SI Appendix, Table S3). Also, the balance and truncal stability of the patient were evaluated using a computerized dynamic posturography (CDP) apparatus by an examiner who was blinded as to treatment, which assesses sway under six conditions (37). The patient was subsequently started on chlorzoxazone, 500 mg QID, and returned after 1 mo of therapy. Repeat SARA testing revealed a mean score of 18.3. Repeat CDP showed an ∼10% improvement in the composite score with a marked improvement in condition 3, in which the patient relies only on proprioceptive and vestibular cues. Unfortunately, follow-up after 6 mo on the medication revealed continued disease progression. Our results suggest that activation of endogenous SK and BK channels in these BK mutant patients may provide symptomatic improvement. Continued disease progression in this case may indicate that chlorzoxazone has no effect on blocking the mutant BKG354S channel (SI Appendix, Fig. S4).

Discussion

The diversity of genetic and mutational defects identified for SCAs suggests that multiple pathophysiological mechanisms lead to a common clinical and pathological phenotype. The numerous ion channel mutations implicated in the ataxias indicate that disturbances of intracellular ionic milieu might be a frequent pathophysiological mechanism affecting Purkinje cells (14, 6, 3841). However, the pathogenic mechanisms coupling disturbed membrane ionic flux to pathological changes at the cellular and subcellular level remain to be elucidated. Previous studies have shown that expression of mutant KCND3-encoded channels (KV4.3) from SCA19 ataxia patients in cultured Purkinje cells reduces viability and dendritic outgrowth (42). In the present study, we demonstrate that a spontaneously occurring mutation in KCNMA1-encoded channels (BK), predicting an amino acid change in the selectivity filter of the channel, leads to the LOF of the BK channel phenotype with severely reduced channel conductance with loss of K+ selectivity. In addition, the patient affected by this mutation presents a syndrome of progressive cerebellar ataxia, cognitive impairment, and dyskinesia. At least seven other reported KCNMA1 LOF mutations are associated with cerebellar impairment, and two others with cognitive impairment (13). Moreover, AAV-mediated delivery of the BKG354S channel, but not the BKWT channel, produced ataxic gait in mice. Genetic ablation of the KCNMA1 also led to ataxia in mice. Together, these observations indicate a strong dependency of cerebellar function on normal BK channel activity.

BK channels are similar to other voltage-gated potassium channels in that they contain a highly conserved 352-TVGYG-356 sequence in the pore-forming domain known as the selectivity filter (Fig. 3), precisely the moiety where the G354S mutation is predicted in the present patient. It is instructive that other spontaneous mutations in the BK channel lead to enhanced rather than reduced BK channel activity and have a distinct clinical picture. D434G (BKD434G), within the RCK domain, is a GOF mutation yielding a channel that is more sensitive to Ca2+ and that opens faster and at more negative voltages (14). N995S (BKN995S) is a GOF mutation reported in three individuals causing a leftward shift of the conductance–voltage (G–V) curve. The GOF mutations are not associated with ataxia or cerebellar atrophy, but instead have been associated with epileptic syndromes and paroxysmal dyskinesia.

A full assessment of the probable heterotetramerization of BKWT and BKG354S subunits in the same channel is beyond the scope of this study. In our preliminary results, unitary currents studied by both single-channel patch clamp and by noise analysis of macroscopic currents in membranes from oocytes injected previously with cRNA for both types of proteins, never showed intermediary conductance. On the other hand, macroscopic K+ currents recorded from these cells showed evidence of heterotetramerization. First, BKWT expression, as measured by the amplitude of the macroscopic K+ currents, was affected by the likely coexpression, in the same oocyte, of BKG354S, suggesting dominant-negative effect and in agreement with the mitochondrial studies. Second, the time constants of the putative BKWT-G354S activation kinetics sit in between the BKWT and BKG354S values. Third, the voltage dependence of the activation kinetics resembles that of pure BKG354S channels: They are virtually voltage independent (SI Appendix, Fig. S1).

An important aspect of this BKG354S channel phenotype is that it conducts Na+ with the permeability of ∼20% of the K+ permeability. This BKG354S channel Na+ permeability may play an important role in the clinicopathological phenotype since during neuronal activity BK channels normally act by damping excitatory processes mediated by an increase in internal Ca2+. In other words, the increased Na+ permeability may be as significant a deleterious property of this mutant channel as the dramatic depression of the K+ conductance. The mutant channel therefore should conduct Na+ inwardly when activated, producing longer periods of depolarization. Under physiological intracellular and extracellular concentrations of Na+ and K+, the current carried by these mutant channels has a reversal potential near −40 mV, and therefore the BKG354S effect on the membrane potential is toward keeping it near −40 mV, most likely above the threshold voltage for action potential generation by neurons. Thus, we hypothesize that when the plasma membrane BKG354S channel is activated it should act by increasing neurotransmitter release and should not be able to modulate action potential duration adequately.

The unexpected blocking effect of NS1619 on the BKG354S conductance (to K+ and more importantly to Na+ as stated above) can explain the benefit of this BK activator compound (Fig. 6) on the reduced PC12 neurite outgrowth and cell viability (Fig. 7) and on the mitochondrial content, also in PC12 cells (Fig. 8).

On the other hand, the presence of BKG354S mutant channels both in the plasma membrane and the mitochondrial membrane would lead to the following: first, an increase in cytoplasmic Na+ concentration during neuronal activity similar to that produced during ischemia (43); and second, as a consequence of the reduction or loss of mitoBK, the cytoprotective effect of the activation of mitoBK is lost (44). Therefore, NS1619 has the double beneficial role of inhibiting the mutant channels reducing the deleterious effect of the mutant channels present in the plasma and mitochondrial membrane and activating the remaining BKWT channels partially recovering the cytoprotective effect of mitoBK channel.

The transient beneficial effect of chlorzoxazone, a mixed SK/BK channel activator, may be attributed to the activation of residual SK channels as well, which may have even been up-regulated in the disease context.

Although the association of other LOF K+ channel mutations in the ataxia (1, 3, 6) suggests that a persistent depolarized neuronal state is a common pathological pathway, determining the subcellular sites of action of the toxic effect of these mutations will provide significant insight into the pathogenesis of SCAs. BK channels are widely expressed throughout the central nervous system and are abundant in cerebellar Purkinje cells. Together with SK channels, they play a key role in quickly repolarizing the cell membrane when the intracellular Ca2+ concentration is increased, as well as in shaping the afterhyperpolarization potential, especially in mature Purkinje cells (45, 46). Both BK and SK channels are also present in membranes of organelles, for example in the inner mitochondrial membrane (47) and in the inner nuclear membrane (48, 49), where they have similar biophysical and pharmacological properties. In mitochondria, they play a role in calcium retention capacity coupled to the permeability transition pore.

Thus, in the mitochondrial context, the effects of BKG354S are different. In the present study, BKG354S confers a toxic effect in cultured cell lines and impairs neurite outgrowth in neuronal precursor cells. We also find that BKG354S is associated with dysfunctional, disrupted, and depleted mitochondria. Knockdown of the BK channel gene using siRNA replicates these cellular abnormalities. The channel mitoBK, one splicing variant of BKWT, is thought to protect the mitochondrial matrix from Ca2+ overload by depolarizing the inner membrane and therefore by decreasing its polarization voltage, the main driving force for Ca2+ entry (44, 50). The driving force for K+ is the voltage across the inner membrane (approximately −160 mV negative in the matrix), since K+ concentration in the cytoplasm and in the mitochondrial matrix are similar. In the case of BKG354S being present in the inner membrane of mitochondria, coassembled or not with mitoBK, its decreased unitary conductance and its partial Na+ permeability must be considered. The decreased unitary conductance would disrupt the protective effect of the channel against intracellular Ca2+ increases and mitochondrial Ca2+ buffering, a hypothesis corroborated by our findings in this present work and also by effects of experimentally blockade with paxillin, a specific BK blocker (51). As explained above, the fact that a known BK channel activator such as NS1619 blocks the BKG354S mutant channel suggests that the improved survival of cells expressing the mutant may result from both actions of the drug, particularly on mitoBK, i.e., blocking the deleterious Na+ conductance of the mutant channel as well as increasing the activity of BKWT channels only (Fig. 6) (44).

At present, there are no selective BK activators approved for human use. However, based on these findings, we performed an empiric therapeutic challenge to explore the effect of a nonspecific BK/SK activator, chlorzoxazone, in the proband. The patient was evaluated by semiquantitative clinical and performance measures by blinded investigators, before and after the initiation of a standard therapeutic dose of this muscle relaxant. A statistically significant improvement was noted in the patient, although disease progression continued despite therapy. One explanation for these observations is that the improvement resulted from the effect on the plasma membrane SK and BK channels, while the disease progressed due to a lack of effect of the drug on the altered ion selectivity and on mitochondrial BK channels.

Mice with targeted deletion of BK channel α-subunit (BK−/−) have predominantly a cerebellar phenotype with intention tremor, gait incoordination, and impaired eye-blink conditioning (a classic form of cerebellar motor learning). Surprisingly, these animals show no cerebellar degeneration. We found a similar picture in a mouse model induced by AAV delivery of the BKG354S mutation. This is in contrast to two siblings with the more widespread motor system disorder and marked cerebellar atrophy, attributed to homozygous LOF mutations in the BK channel. We speculate that the difference relates to age differences, or the role of compensatory pathways. The present patient has a milder phenotype in which progressive ataxia began at age 8 y, attributed to a BK channel LOF mutation.

Studies of a mouse model for another form of ataxia, SCA1, provided a possible explanation that incorporates an integrated model. In SCA1 mice, induced by genetic overexpression of the ataxin-1 protein bearing an expanded polyglutamine repeat, secondary loss of BK channel expression is accompanied by reduced spontaneous discharges. The discharges reappear during Purkinje cell shrinkage. The authors were able to rescue the cells from shrinkage by pharmacologic activation or overexpression of normal BK channels. They suggest that the shrinkage is a homeostatic adaptation to restore Purkinje cell firing in the absence of BK channels (52). However, again the viability of the mitochondria has not been evaluated in any of these mouse ataxia models.

In summary, our studies identify another genetic cause of progressive ataxia. This LOF mutation in the selectivity filter of the BK channel supports the view that delayed neuronal repolarization due to impaired potassium channel function in the membrane in addition to reduced BK channel function in the mitochondria are potential mechanisms for Purkinje cell degeneration leading to cerebellar ataxia as well as developmental delay.

Materials and Methods

The materials and methods are described at length in SI Appendix, SI Materials and Methods. This includes human DNA samples, WES, cell culture, transient transfection, immunofluorescence staining, mitochondrial staining, cell death analysis, preparation of cell membranes and mitochondrial fractionation, antibody, retroviral transduction, live-cell imaging, expression in Xenopus oocytes, electrophysiology, injection of AAV9 into the ventricle of neonatal WT mice, moving platform posturography, and statistical analysis. Studies using human subjects were carried out with informed consent in accordance with the Institutional Review Board at the University of Chicago.

Data Availability.

All DNA plasmids and bacterial strains used in this study are available at Dryad (https://doi.org/10.5061/dryad.1ns1rn8qk). All data generated and analyzed over the course of the current study are included within the manuscript or SI Appendix.

Supplementary Material

Supplementary File
Supplementary File
Download video file (11.3MB, avi)
Supplementary File
Download video file (11.3MB, avi)
Supplementary File
Download video file (11.3MB, avi)
Supplementary File
Download video file (11.3MB, avi)
Supplementary File
Download video file (11.3MB, avi)
Supplementary File
Download video file (11.3MB, avi)

Acknowledgments

This work was supported by NIH Grants R01NS082788, R01NS094665, and R21NS094872-01 (to C.M.G.), and R01GM030376 and R21-EY027101 (to F.B.); by University of Chicago Big Vision Grant (to C.M.G.); and by Fondecyt Grants 1150273 and 1190203, and the US Air Force Office of Scientific Research under Award A9550-16-1-0384 (to R.L.). This work was also supported by Centro Interdisciplinario de Neurociencia de Valparaiso, a Millennium Institute supported by the Millennium Scientific Initiative of the Chilean Ministry of Economy, Development, and Tourism (P029-022-F). We thank Yimei Chen at the University of Chicago Electron Microscopy Core Facility for the sample preparation and imaging service. We thank Dr. Vytas Bindokas at the University of Chicago Microscopy Core Facility for the imaging service.

Footnotes

The authors declare no competing interest.

This article is a PNAS Direct Submission.

Data deposition: All DNA plasmids and bacterial strains used in this study are available at Dryad (https://doi.org/10.5061/dryad.1ns1rn8qk).

This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1920008117/-/DCSupplemental.

References

  • 1.Browne D. L., et al. , Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nat. Genet. 8, 136–140 (1994). [DOI] [PubMed] [Google Scholar]
  • 2.Coutelier M., et al. , A recurrent mutation in CACNA1G alters Cav3.1 T-type calcium-channel conduction and causes autosomal-dominant cerebellar ataxia. Am. J. Hum. Genet. 97, 726–737 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.D’Adamo M. C., Imbrici P., Sponcichetti F., Pessia M., Mutations in the KCNA1 gene associated with episodic ataxia type-1 syndrome impair heteromeric voltage-gated K+ channel function. FASEB J. 13, 1335–1345 (1999). [DOI] [PubMed] [Google Scholar]
  • 4.Duarri A., et al. , Mutations in potassium channel kcnd3 cause spinocerebellar ataxia type 19. Ann. Neurol. 72, 870–880 (2012). [DOI] [PubMed] [Google Scholar]
  • 5.Duarri A., et al. , The L450F [corrected] mutation in KCND3 brings spinocerebellar ataxia and Brugada syndrome closer together. Neurogenetics 14, 257–258 (2013). [DOI] [PubMed] [Google Scholar]
  • 6.Figueroa K. P., et al. , KCNC3: Phenotype, mutations, channel biophysics—a study of 260 familial ataxia patients. Hum. Mutat. 31, 191–196 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Figueroa K. P., et al. , Frequency of KCNC3 DNA variants as causes of spinocerebellar ataxia 13 (SCA13). PLoS One 6, e17811 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Jen J., Calcium channelopathies in the central nervous system. Curr. Opin. Neurobiol. 9, 274–280 (1999). [DOI] [PubMed] [Google Scholar]
  • 9.Marelli C., Cazeneuve C., Brice A., Stevanin G., Dürr A., Autosomal dominant cerebellar ataxias. Rev. Neurol. (Paris) 167, 385–400 (2011). [DOI] [PubMed] [Google Scholar]
  • 10.Nascimento F. A., Andrade D. M., Myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK) is caused by heterozygous KCNC1 mutations. Epileptic Disord. 18, 135–138 (2016). [DOI] [PubMed] [Google Scholar]
  • 11.Smets K., et al. , First de novo KCND3 mutation causes severe Kv4.3 channel dysfunction leading to early onset cerebellar ataxia, intellectual disability, oral apraxia and epilepsy. BMC Med. Genet. 16, 51 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Latorre R., et al. , Molecular determinants of BK channel functional diversity and functioning. Physiol. Rev. 97, 39–87 (2017). [DOI] [PubMed] [Google Scholar]
  • 13.Bailey C. S., Moldenhauer H. J., Park S. M., Keros S., Meredith A. L., KCNMA1-linked channelopathy. J. Gen. Physiol. 151, 1173–1189 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Du W., et al. , Calcium-sensitive potassium channelopathy in human epilepsy and paroxysmal movement disorder. Nat. Genet. 37, 733–738 (2005). [DOI] [PubMed] [Google Scholar]
  • 15.Sausbier M., et al. , Cerebellar ataxia and Purkinje cell dysfunction caused by Ca2+-activated K+ channel deficiency. Proc. Natl. Acad. Sci. U.S.A. 101, 9474–9478 (2004). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Liang L., et al. , De novo loss-of-function KCNMA1 variants are associated with a new multiple malformation syndrome and a broad spectrum of developmental and neurological phenotypes. Hum. Mol. Genet. 28, 2937–2951 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Tabarki B., AlMajhad N., AlHashem A., Shaheen R., Alkuraya F. S., Homozygous KCNMA1 mutation as a cause of cerebellar atrophy, developmental delay and seizures. Hum. Genet. 135, 1295–1298 (2016). [DOI] [PubMed] [Google Scholar]
  • 18.Zhang Z. B., Tian M. Q., Gao K., Jiang Y. W., Wu Y., De novo KCNMA1 mutations in children with early-onset paroxysmal dyskinesia and developmental delay. Mov. Disord. 30, 1290–1292 (2015). [DOI] [PubMed] [Google Scholar]
  • 19.Yeşil G., et al. , Expanding the phenotype of homozygous KCNMA1 mutations; dyskinesia, epilepsy, intellectual disability, cerebellar and corticospinal tract atrophy. Balkan Med. J. 35, 336–339 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Edwards G., Niederste-Hollenberg A., Schneider J., Noack T., Weston A. H., Ion channel modulation by NS 1619, the putative BKCa channel opener, in vascular smooth muscle. Br. J. Pharmacol. 113, 1538–1547 (1994). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Holland M., Langton P. D., Standen N. B., Boyle J. P., Effects of the BKCa channel activator, NS1619, on rat cerebral artery smooth muscle. Br. J. Pharmacol. 117, 119–129 (1996). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Olesen S. P., Munch E., Moldt P., Drejer J., Selective activation of Ca2+-dependent K+ channels by novel benzimidazolone. Eur. J. Pharmacol. 251, 53–59 (1994). [DOI] [PubMed] [Google Scholar]
  • 23.Liu Y.-C., Lo Y.-K., Wu S.-N., Stimulatory effects of chlorzoxazone, a centrally acting muscle relaxant, on large conductance calcium-activated potassium channels in pituitary GH3 cells. Brain Res. 959, 86–97 (2003). [DOI] [PubMed] [Google Scholar]
  • 24.Li X., et al. , De novo BK channel variant causes epilepsy by affecting voltage gating but not Ca2+ sensitivity. Eur. J. Hum. Genet. 26, 220–229 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Adzhubei I., Jordan D. M., Sunyaev S. R., Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet. 76, 7.20.1–7.20.41 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ng P. C., Henikoff S., SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812–3814 (2003). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Makhseed N., et al. , Carnitine transporter defect due to a novel mutation in the SLC22A5 gene presenting with peripheral neuropathy. J. Inherit. Metab. Dis. 27, 778–780 (2004). [DOI] [PubMed] [Google Scholar]
  • 28.Srivastava S., et al. , BRAT1 mutations present with a spectrum of clinical severity. Am. J. Med. Genet. A. 170, 2265–2273 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Zatz M., de Paula F., Starling A., Vainzof M., The 10 autosomal recessive limb-girdle muscular dystrophies. Neuromuscul. Disord. 13, 532–544 (2003). [DOI] [PubMed] [Google Scholar]
  • 30.Tao X., Hite R. K., MacKinnon R., Cryo-EM structure of the open high-conductance Ca2+-activated K+ channel. Nature 541, 46–51 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Heginbotham L., Lu Z., Abramson T., MacKinnon R., Mutations in the K+ channel signature sequence. Biophys. J. 66, 1061–1067 (1994). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Gessner G., et al. , Molecular mechanism of pharmacological activation of BK channels. Proc. Natl. Acad. Sci. U.S.A. 109, 3552–3557 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Miyazaki Y., Du X., Muramatsu S., Gomez C. M., An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron. Sci. Transl. Med. 8, 347ra94 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Du X., et al. , Second cistron in CACNA1A gene encodes a transcription factor mediating cerebellar development and SCA6. Cell 154, 118–133 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Romano S., et al. , Riluzole in patients with hereditary cerebellar ataxia: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 14, 985–991 (2015). [DOI] [PubMed] [Google Scholar]
  • 36.Ristori G., et al. , Riluzole in cerebellar ataxia: A randomized, double-blind, placebo-controlled pilot trial. Neurology 74, 839–845 (2010). [DOI] [PubMed] [Google Scholar]
  • 37.Schmitz-Hübsch T., et al. , Scale for the assessment and rating of ataxia: Development of a new clinical scale. Neurology 66, 1717–1720 (2006). [DOI] [PubMed] [Google Scholar]
  • 38.Imbrici P., D’Adamo M. C., Cusimano A., Pessia M., Episodic ataxia type 1 mutation F184C alters Zn2+-induced modulation of the human K+ channel Kv1.4-Kv1.1/Kvbeta1.1. Am. J. Physiol. Cell Physiol. 292, C778–C787 (2007). [DOI] [PubMed] [Google Scholar]
  • 39.Corbett M. A., et al. , Dominant KCNA2 mutation causes episodic ataxia and pharmacoresponsive epilepsy. Neurology 87, 1975–1984 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Zerr P., Adelman J. P., Maylie J., Characterization of three episodic ataxia mutations in the human Kv1.1 potassium channel. FEBS Lett. 431, 461–464 (1998). [DOI] [PubMed] [Google Scholar]
  • 41.Ophoff R. A., et al. , Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87, 543–552 (1996). [DOI] [PubMed] [Google Scholar]
  • 42.Irie T., Matsuzaki Y., Sekino Y., Hirai H., Kv3.3 channels harbouring a mutation of spinocerebellar ataxia type 13 alter excitability and induce cell death in cultured cerebellar Purkinje cells. J. Physiol. 592, 229–247 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Murata M., Akao M., O’Rourke B., Marbán E., Mitochondrial ATP-sensitive potassium channels attenuate matrix Ca2+ overload during simulated ischemia and reperfusion: Possible mechanism of cardioprotection. Circ. Res. 89, 891–898 (2001). [DOI] [PubMed] [Google Scholar]
  • 44.Sato T., Saito T., Saegusa N., Nakaya H., Mitochondrial Ca2+-activated K+ channels in cardiac myocytes: A mechanism of the cardioprotective effect and modulation by protein kinase A. Circulation 111, 198–203 (2005). [DOI] [PubMed] [Google Scholar]
  • 45.Womack M. D., Khodakhah K., Characterization of large conductance Ca2+-activated K+ channels in cerebellar Purkinje neurons. Eur. J. Neurosci. 16, 1214–1222 (2002). [DOI] [PubMed] [Google Scholar]
  • 46.Womack M. D., Hoang C., Khodakhah K., Large conductance calcium-activated potassium channels affect both spontaneous firing and intracellular calcium concentration in cerebellar Purkinje neurons. Neuroscience 162, 989–1000 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Singh H., et al. , MitoBKCa is encoded by the Kcnma1 gene, and a splicing sequence defines its mitochondrial location. Proc. Natl. Acad. Sci. U.S.A. 110, 10836–10841 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Singh H., Stefani E., Toro L., Intracellular BKCa (iBKCa) channels. J. Physiol. 590, 5937–5947 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Li B., Gao T. M., Functional role of mitochondrial and nuclear BK channels. Int. Rev. Neurobiol. 128, 163–191 (2016). [DOI] [PubMed] [Google Scholar]
  • 50.Gavin C. E., Gunter K. K., Gunter T. E., Manganese and calcium efflux kinetics in brain mitochondria. Relevance to manganese toxicity. Biochem. J. 266, 329–334 (1990). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Xu W., et al. , Cytoprotective role of Ca2+-activated K+ channels in the cardiac inner mitochondrial membrane. Science 298, 1029–1033 (2002). [DOI] [PubMed] [Google Scholar]
  • 52.Dell’Orco J. M., et al. , Neuronal atrophy early in degenerative ataxia is a compensatory mechanism to regulate membrane excitability. J. Neurosci. 35, 11292–11307 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Bezanilla F., Armstrong C. M., Inactivation of the sodium channel. I. Sodium current experiments. J. Gen. Physiol. 70, 549–566 (1977). [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary File
Supplementary File
Download video file (11.3MB, avi)
Supplementary File
Download video file (11.3MB, avi)
Supplementary File
Download video file (11.3MB, avi)
Supplementary File
Download video file (11.3MB, avi)
Supplementary File
Download video file (11.3MB, avi)
Supplementary File
Download video file (11.3MB, avi)

Data Availability Statement

All DNA plasmids and bacterial strains used in this study are available at Dryad (https://doi.org/10.5061/dryad.1ns1rn8qk). All data generated and analyzed over the course of the current study are included within the manuscript or SI Appendix.


Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES